Do mGluR5 positive allosteric modulators increase NMDA-induced phosphorylation of extracellular signal-regulated kinase (ERK)?

dc.contributor.authorBoll, Jette Bisgaard
dc.contributor.authorLeist, Marcel
dc.contributor.authorLarsen, S. A.
dc.contributor.authorLundbeck, H.
dc.date.accessioned2020-12-22T09:57:15Z
dc.date.available2020-12-22T09:57:15Z
dc.date.issued2005eng
dc.description.abstractOne of the suggested hallmarks in Schizophrenia is a hypo-function of the NMDA system. One attempt to overcome the hypofunction of the glutamate system is to modulate the mGluR5 receptors. Since it is quite problematic to activate the glutamatergic system without excitotoxic side effects, it would be desirable to use mGluR5 positive allosteric modulators instead of i.e. NMDA or mGluR5 agonists. We have used murine cortical neurons to establish a model for measuring single cell ERK phosphorylation. Cortical neurons cultured for 7 – 8 days in vitro were stimulated very briefl y with NMDA, following by fi xation with 4% paraformaldehyde. Subsequently, the cells were stained with an anti-phospho-p44/42 MAP kinase (pERK1/2) antibody and then a fl uorescent secondary antibody. The fl uorescent intensity in both the cytoplasm and nucleus of single cells was measured on an ArrayScanner® (Cellomics). Having the method set up, we wanted to address, if the mixed cortical cultures were suitable to study NMDA- and mGluR5 receptor interaction. The cultures expressed NMDA and mGluR5 receptors, and the pERK response was dependent on the concentration of NMDA. The results obtained with single cell pERK measurement were confi rmed by Western blotting and by pharmacological intervention. To examine effect of mGluR5 agonists and allosteric modulators, several compounds were tested: (RS)-2- Chloro-5-hydroxyphenylglycine (CHPG), (RS)-3,5-dihydroxyphenylglycine (DHPG), 3,3’-difl uorobenzaldazine (DFB), N-{4-chloro-2-[(1,3-dioxo-1,3- dihydro-2H-isoindol-2-yl)methyl] phenyl}-2-hydroxybenzamide (CPPHA) and 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (8q). We observed a synergistic effect on the NMDA response and the modulators have no effect on their own. Measurement of ERK phosphorylation is a new way to measure NMDA enhancement by mGluR5 on single cell level in cortical neurons with high throughput and statistical validity.eng
dc.description.versionpublishedeng
dc.identifier.doi10.1016/j.neuropharm.2005.06.013eng
dc.identifier.urihttps://kops.uni-konstanz.de/handle/123456789/52223
dc.language.isoengeng
dc.rightsterms-of-use
dc.rights.urihttps://rightsstatements.org/page/InC/1.0/
dc.subject.ddc570eng
dc.titleDo mGluR5 positive allosteric modulators increase NMDA-induced phosphorylation of extracellular signal-regulated kinase (ERK)?eng
dc.typeJOURNAL_ARTICLEeng
dspace.entity.typePublication
kops.citation.bibtex
@article{Boll2005mGluR-52223,
  year={2005},
  doi={10.1016/j.neuropharm.2005.06.013},
  title={Do mGluR5 positive allosteric modulators increase NMDA-induced phosphorylation of extracellular signal-regulated kinase (ERK)?},
  number={Suppl},
  volume={49},
  issn={0028-3908},
  journal={Neuropharmacology},
  author={Boll, Jette Bisgaard and Leist, Marcel and Larsen, S. A. and Lundbeck, H.},
  note={Meeting Abstract}
}
kops.citation.iso690BOLL, Jette Bisgaard, Marcel LEIST, S. A. LARSEN, H. LUNDBECK, 2005. Do mGluR5 positive allosteric modulators increase NMDA-induced phosphorylation of extracellular signal-regulated kinase (ERK)?. In: Neuropharmacology. Elsevier. 2005, 49(Suppl), pp. 235. ISSN 0028-3908. eISSN 1873-7064. Available under: doi: 10.1016/j.neuropharm.2005.06.013deu
kops.citation.iso690BOLL, Jette Bisgaard, Marcel LEIST, S. A. LARSEN, H. LUNDBECK, 2005. Do mGluR5 positive allosteric modulators increase NMDA-induced phosphorylation of extracellular signal-regulated kinase (ERK)?. In: Neuropharmacology. Elsevier. 2005, 49(Suppl), pp. 235. ISSN 0028-3908. eISSN 1873-7064. Available under: doi: 10.1016/j.neuropharm.2005.06.013eng
kops.citation.rdf
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/52223">
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Leist, Marcel</dc:contributor>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/52223"/>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>Lundbeck, H.</dc:contributor>
    <dcterms:abstract xml:lang="eng">One of the suggested hallmarks in Schizophrenia is a hypo-function of the NMDA system. One attempt to overcome the hypofunction of the glutamate system is to modulate the mGluR5 receptors. Since it is quite problematic to activate the glutamatergic system without excitotoxic side effects, it would be desirable to use mGluR5 positive allosteric modulators instead of i.e. NMDA or mGluR5 agonists. We have used murine cortical neurons to establish a model for measuring single cell ERK phosphorylation. Cortical neurons cultured for 7 – 8 days in vitro were stimulated very briefl y with NMDA, following by fi xation with 4% paraformaldehyde. Subsequently, the cells were stained with an anti-phospho-p44/42 MAP kinase (pERK1/2) antibody and then a fl uorescent secondary antibody. The fl uorescent intensity in both the cytoplasm and nucleus of single cells was measured on an ArrayScanner® (Cellomics). Having the method set up, we wanted to address, if the mixed cortical cultures were suitable to study NMDA- and mGluR5 receptor interaction. The cultures expressed NMDA and mGluR5 receptors, and the pERK response was dependent on the concentration of NMDA. The results obtained with single cell pERK measurement were confi rmed by Western blotting and by pharmacological intervention. To examine effect of mGluR5 agonists and allosteric modulators, several compounds were tested: (RS)-2- Chloro-5-hydroxyphenylglycine (CHPG), (RS)-3,5-dihydroxyphenylglycine (DHPG), 3,3’-difl uorobenzaldazine (DFB), N-{4-chloro-2-[(1,3-dioxo-1,3- dihydro-2H-isoindol-2-yl)methyl] phenyl}-2-hydroxybenzamide (CPPHA) and 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (8q). We observed a synergistic effect on the NMDA response and the modulators have no effect on their own. Measurement of ERK phosphorylation is a new way to measure NMDA enhancement by mGluR5 on single cell level in cortical neurons with high throughput and statistical validity.</dcterms:abstract>
    <dc:contributor>Larsen, S. A.</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-12-22T09:57:15Z</dcterms:available>
    <dc:creator>Lundbeck, H.</dc:creator>
    <dc:rights>terms-of-use</dc:rights>
    <dc:creator>Boll, Jette Bisgaard</dc:creator>
    <dcterms:issued>2005</dcterms:issued>
    <dcterms:title>Do mGluR5 positive allosteric modulators increase NMDA-induced phosphorylation of extracellular signal-regulated kinase (ERK)?</dcterms:title>
    <dc:language>eng</dc:language>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Larsen, S. A.</dc:creator>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:contributor>Boll, Jette Bisgaard</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-12-22T09:57:15Z</dc:date>
    <dc:creator>Leist, Marcel</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
  </rdf:Description>
</rdf:RDF>
kops.description.commentMeeting Abstracteng
kops.flag.isPeerReviewedfalseeng
kops.flag.knbibliographyfalse
kops.sourcefieldNeuropharmacology. Elsevier. 2005, <b>49</b>(Suppl), pp. 235. ISSN 0028-3908. eISSN 1873-7064. Available under: doi: 10.1016/j.neuropharm.2005.06.013deu
kops.sourcefield.plainNeuropharmacology. Elsevier. 2005, 49(Suppl), pp. 235. ISSN 0028-3908. eISSN 1873-7064. Available under: doi: 10.1016/j.neuropharm.2005.06.013deu
kops.sourcefield.plainNeuropharmacology. Elsevier. 2005, 49(Suppl), pp. 235. ISSN 0028-3908. eISSN 1873-7064. Available under: doi: 10.1016/j.neuropharm.2005.06.013eng
relation.isAuthorOfPublicationd166cc79-683e-4b5f-b4a0-8ccdd3d02bbc
relation.isAuthorOfPublication.latestForDiscoveryd166cc79-683e-4b5f-b4a0-8ccdd3d02bbc
source.bibliographicInfo.fromPage235eng
source.bibliographicInfo.issueSuppleng
source.bibliographicInfo.volume49eng
source.identifier.eissn1873-7064eng
source.identifier.issn0028-3908eng
source.periodicalTitleNeuropharmacologyeng
source.publisherElseviereng

Dateien